Novo Nordisk A/S
https://www.novonordisk.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novo Nordisk A/S
Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy
Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Contraline/Population Council, Proveca/Cessatech, Vivtex/Equillium and more.
Novo Nordisk’s Monlunabant Expectations Dashed By Phase II Data
Mid-stage clinical data show why cannabinoid receptor inverse agonism is an unfavored approach to obesity treatment.
100 Years In India – GSK’s Secret Sauce To Not Just Stay Relevant But Thrive
GlaxoSmithKline Pharmaceuticals’ MD tells Scrip how the company has been able to reinvent itself, contemporize brands and get supply chain innovation right as the UK-headquartered firm marks 100 years of operations in India. GSK’s equivalent of the 'Amazon model' for vaccine ordering and the new temples of industry are some of the other facets the executive discussed in the first instalment of this two-part interview.
QL Biopharm Fires China’s First Shot At Monthly GLP-1 Obesity Drug
Without a placebo control arm, ZT002, a once-monthly GLP-1 receptor agonist from the Chinese biotech, reduced body weight by 17.1% from baseline at 30 weeks in Chinese obese patients, data from a Phase Ic clinical study showed.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Carbometrics
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice